1 Great Valley Parkway
About TELA Bio
TELA Bio, Inc. is a privately-owned company focused on bringing innovative, cost-effective, surgical reconstruction solutions to surgeons, hospitals and patients.
Founders: Antony Koblish and Maarten Persenaire
Founder and CEO: Antony Koblish
Founder and CMO: Maarten Persenaire
CTO: Skott Greenhalgh
18 articles with TELA Bio
TELA Bio® Announces 510(k) Clearance for Restella™ Reconstructive BioScaffolds for Reconstructive Surgery
Innovative product portfolio based on TELA Bio's proven technology platform advances the design of biologic-based materials for reconstructive surgery.
TELA Bio®, Inc. announced that the company will present at the 18th Annual Needham Healthcare Conference to be held April 9-10, 2019 at the Westin Grand Central Hotel in New York City.
TELA Bio®, Inc., a surgical reconstruction company leading the development and commercialization of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the first patient has been treated with OviTex RBSs in Europe.
TELA Bio begins commercialization for Large Size OviTex® Reinforced BioScaffolds for Hernia Repair and Abdominal Wall Reconstruction after Aroa Biosurgery receives 510k clearance.
1,000 cm(2) device now commercially available in the U.S. rounds out portfolio of surgical mesh for full range of complex surgical procedures
TELA Bio is a surgical reconstruction company leading the development and commercialization of OviTex® Reinforced BioScaffolds for soft tissue repair
TELA Bio® Announces Publication of Case Series Evaluating OviTex® Reinforced BioScaffolds in Hiatal and Inguinal Hernia Repair
Two papers report no hernia recurrences during postoperative period, highlight advantages in repair reinforcement and pain management.
TELA Bio® Announces Initial Data from BRAVO Study of OviTex® Reinforced BioScaffolds for Ventral Hernia Repair
Early outcomes from post-market clinical study presented at Abdominal Wall Reconstruction Conference in Washington, DC.
Distinct class of surgical implants for hernia procedures to launch in Europe
Surgical reconstruction company looks to forge long-term relationship with strategic investment group.
Affiliate of leading integrated delivery network to invest $1 million in TELA Bio to form a strategic partnership in research and education
TELA Bio Announces Results from Retrospective Study of OviTex Reinforced BioScaffolds for Abdominal Wall Reconstruction
Data presented at Americas Hernia Society International Hernia Congress 2018 show low recurrence and complication rates.
TELA Bio today announced that Greg Firestone has joined the company as VP of strategic customer relations and will be responsible for developing collaborative relationships.
TELABio Announces Commercial Launch Of OviTex Reinforced BioScaffolds For Ventral Hernia Repair And Abdominal Wall Reconstruction
TELABio Release: Results From Studies Of OviTex Reinforced BioScaffolds Presented At Abdominal Wall Reconstruction Conference